KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Invested Capital (2016 - 2020)

Inovio Pharmaceuticals' Return on Invested Capital history spans 6 years, with the latest figure at 0.49% for Q3 2020.

  • For Q3 2020, Return on Invested Capital rose 92.0% year-over-year to 0.49%; the TTM value through Sep 2020 reached 0.49%, up 92.0%, while the annual FY2019 figure was 2.38%, 154.0% down from the prior year.
  • Return on Invested Capital for Q3 2020 was 0.49% at Inovio Pharmaceuticals, up from 0.6% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.43% in Q3 2016 and bottomed at 5.19% in Q4 2019.
  • The 5-year median for Return on Invested Capital is 0.8% (2019), against an average of 1.12%.
  • The largest annual shift saw Return on Invested Capital plummeted -419bps in 2019 before it soared 92bps in 2020.
  • A 5-year view of Return on Invested Capital shows it stood at 0.43% in 2016, then crashed by -50bps to 0.64% in 2017, then tumbled by -57bps to 1.01% in 2018, then plummeted by -416bps to 5.19% in 2019, then skyrocketed by 91bps to 0.49% in 2020.
  • Per Business Quant, the three most recent readings for INO's Return on Invested Capital are 0.49% (Q3 2020), 0.6% (Q2 2020), and 1.11% (Q1 2020).